Prosight Management’s Compass Therapeutics CMPX Stock Holding History

Prosight Management’s Portfolio CMPX Stock Details CMPX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-935,157	Closed	-$1.84M	–	37
2023 Q3	$1.84M	Sell	935,157 -148,840	-14%	-$368K	0.58%	31
2023 Q2	$3.45M	Buy	1,083,997 +405,697	+60%	+$1.27M	1.01%	28
2023 Q1	$2.22M	Buy	+678,300	New	+$2.66M	1.05%	27

Other funds holding CMPX

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Prosight Management's CMPX Position: Q4 2023 in Review

Prosight Management sold out of Compass Therapeutics (CMPX) in Q4 2023, closing a stake of 935,157 shares — an estimated $1.84M sold.

Prosight Management first reported a position in CMPX in Q1 2023 and held it in 3 quarters. The position peaked at $3.45M in Q2 2023. 77 funds tracked by Wall St. Rank hold CMPX as of Q4 2023.

Prosight Management reported no remaining Compass Therapeutics position as of Q4 2023 after selling out during the quarter.
Prosight Management sold 935,157 Compass Therapeutics shares in Q4 2023, an estimated $1.84M.
Prosight Management first reported a position in Compass Therapeutics in Q1 2023 and held it in 3 quarters.
Prosight Management's Compass Therapeutics position peaked at $3.45M in Q2 2023.
77 funds tracked by Wall St. Rank held Compass Therapeutics as of Q4 2023.

Based on Prosight Management's 13F filing for Q4 2023, filed 14 Feb 2024.